Pharma

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and Abbott Laboratories as the top pharmaceutical stocks to watch on June 24th. • These companies are highlighted for their roles in the research, development, manufacturing, and sale of medicines and healthcare products. • This selection serves as a guide for investors looking to monitor high-potential assets within the pharmaceutical sector.

• Indian stock markets declined on Friday, driven primarily by a slump in IT stocks as investors engaged in profit-taking near the 24,150 mark. • Despite the dip, analysts indicate that the broader recovery trend remains stable as long as the market stays above 23,700. • Key companies including Sun Pharma, Tata Motors, and ONGC are drawing investor attention due to strategic repositioning, acquisitions, and new order wins.

• At the Reuters Pharma USA 2026 event, industry experts discussed the shift toward "optichannel" engagement to better influence physician prescribing habits. • AstraZeneca’s IO Women’s Cancer Lead, Dicla Veliz Salce, highlighted that strong clinical trial data alone is often insufficient to change medical behavior. • The panel emphasized that real-world evidence (RWE) is critical, as physicians are more likely to adopt new therapies when they see recurrence risks validated in practical settings.

Supply problems pose risk to health, with common painkillers, epilepsy medication and HRT affectedBritons are facing some of the “most severe” shortages of NHS medicines on record including common painkillers, epilepsy drugs and HRT, health leaders have warned, even forcing some patients with impaired digestive systems to skip meals.The National Pharmacy Association (NPA) has warned that medicine shortages pose a “serious risk to patient safety”. Continue reading...

• The Sensex reclaimed the 74,000 mark and rose over 230 points by midday on June 11, 2026, while the Nifty remained above 23,230. • Market recovery was driven by strong buying in private banks and pharma stocks, which offset losses in the IT sector. • This rebound occurs despite severe volatility in US markets, where the Dow Jones fell 1.87% to 49,918.78 and the Nasdaq dropped 1.98% due to Iran-US military escalation.

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and AbbVie as the top three pharmaceutical stocks to watch on June 8th. • These companies operate within the pharmaceutical sector, focusing on the development, manufacturing, and sale of prescription drugs, vaccines, and over-the-counter medicines. • The identification of these specific stocks serves as a guide for investors looking to diversify their portfolios with promising healthcare assets.

• Children’s Tumor Foundation (CTF) CEO Annette Bakker reports that over 5,000 potential treatments for rare diseases are currently shelved by pharmaceutical companies. • The organization is working to rescue these dormant drug candidates to provide options for patients with rare conditions who lack viable therapies. • This initiative addresses a critical gap in drug development where promising compounds are abandoned due to market size or corporate priorities.

• The Pharmaceutical Journal has released a detailed analysis of the new community pharmacy contract. • The report examines whether the new framework will stabilize medicines funding and evaluates its promises regarding long-term systemic reform. • A key focus is placed on how new national prescribing services will integrate with existing local commissioning structures.

• A new outbreak of the Ebola Bundibugyo virus has emerged, affecting the Democratic Republic of Congo, Uganda, and surrounding neighboring countries. • Pharmaceutical and biotech companies are collaborating with global health and humanitarian partners to coordinate a rapid medical response. • This industry involvement is critical to accelerating the containment of the virus and providing necessary treatments to affected populations.

• A landmark week in oncology saw pivotal data released for lung, prostate, bladder, and haematological cancers, alongside major capital investments in AI drug discovery, RNA therapeutics, and gene editing. • New data for embolisation-eligible hepatocellular carcinoma (HCC) showed a 30% incremental improvement over TACE, though overall survival (OS) data remains immature. • The proposed combination of tremelimumab, durvalumab, and lenvatinib plus TACE raises concerns regarding cost, complexity, and patient tolerability compared to the current standard of care.

• Exelixis, Inc. announced positive results from a subgroup analysis of the phase 3 CABINET pivotal trial on May 30, 2026. • The trial demonstrated that CABOMETYX (cabozantinib) provided significant improvements in progression-free survival (PFS) compared to a placebo for patients treating neuroendocrine tumors (NET). • These findings are critical as they provide evidence for the efficacy of cabozantinib in a specific patient population struggling with NET.

• In May 2026, pharmaceutical advancements focused on KRAS, a protein previously deemed "undruggable," with new research exploring the efficacy of the drug daraxonrasib. • A first-line study is currently underway to determine if daraxonrasib can be used earlier in treatment, either as a monotherapy or in combination with chemotherapy. • Public health concerns rose following an outbreak of the Andes strain of hantavirus linked to a Dutch cruise ship, which resulted in three deaths.

• FDA announced new enforcement actions targeting compounding pharmacies producing GLP-1 drugs like semaglutide amid safety concerns. • The crackdown addresses risks from unapproved versions of weight-loss and diabetes medications flooding the market. • This policy shift aims to protect patients from potential contamination and dosing errors in the booming $100 billion GLP-1 sector.

• The US life sciences industry gained momentum in 2026 despite NIH cuts and trade threats, fueled by AI advancements and major pharma deals. • Karius's AI genomic tests for immunocompromised patients detect 50% more pathogens in one day, analyzing millions of DNA reads after testing over 100,000 cases. • Biotech winter ended, shifting focus to preventive health via AI, data, and precise therapeutics amid administration priorities.

OxyContin maker to be replaced by new company aiming to combat opioid crisis as legal settlement takes effectOxyContin maker Purdue Pharma is set to be dissolved and replaced by a company focused on the public good by the week’s end, as a sweeping legal settlement resolving thousands of lawsuits takes effect.A federal judge on Tuesday delivered a criminal sentence to the company to resolve a US Department of Justice investigation – a last necessary step to clear the way for the settlement. Continue reading...

Drugmaker had stalled large-scale UK projects but has now pledged investment at two sites, announced by Keir StarmerBritain’s biggest drugmaker AstraZeneca has said it will invest £300m in the UK in a surprise U-turn after pausing large-scale projects last year.The drugmaker had pulled back projects in Britain after becoming disillusioned with the business environment, including the availability of new medicines on the NHS and drug pricing. Continue reading...

Under settlement, Sackler family will pay state, local and Native American tribal governments, individual victims and othersSign up for the Breaking News US email to get newsletter alerts in your inboxA judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize a settlement of thousands of lawsuits it faces over its role in the opioid crisis.The penalty was agreed to in a 2020 pact to resolve federal civil and criminal investigations it was facing. If the judge signs off, other penalties will not be collected in return for Purdue settling the other lawsuits. Continue reading...

Proposal, a win for RFK Jr’s Maha movement, is a ‘first step’ toward tackling plastic pollution, advocates sayThe Environmental Protection Agency (EPA) proposed on Thursday to include microplastics and pharmaceuticals on a list of contaminants in drinking water for the first time, a step that could lead to new limits on those substances for water utilities.Lee Zeldin, the EPA administrator, said they are responding to Americans who have worried about plastics and pharmaceuticals in their drinking water. The gesture also aims to hand a win to health secretary Robert FKennedy Jr’s Maha movement, which for months has pressured Zeldin to further crack down on environmental contaminants. Continue reading...

Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medicationsGet our breaking news email, free app or daily news podcastAustralia will not cave in to pressure from pharmaceutical giants and the Trump administration by removing consumer price protections on common medications, the health minister, Mark Butler says.Donald Trump imposed a new 100% tariff on branded pharmaceuticals imported into the US overnight, Australian time, trying to force manufacturers to agree to drug-pricing deals or commit to making their products domestically. Continue reading...

• Eli Lilly announced the acquisition of Centessa Pharmaceuticals, a company developing treatments for excessive daytime sleepiness and neurological conditions, in a deal valued at up to $7.8 billion if certain conditions are met. • Centessa shares soared 44% on the news, while Lilly's stock rose 3.7%, helping offset broader market pressures from companies like McCormick. • The deal highlights Big Pharma's aggressive push into neuroscience amid rising demand for sleep disorder therapies, potentially boosting Lilly's pipeline.

• Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies effective March 27, 2026, expanding access for commercially insured patients. • The FDA-approved self-administered spray converts acute paroxysmal supraventricular tachycardia (PSVT) episodes to sinus rhythm in adults. • This coverage decision makes the first-in-class treatment broadly affordable across the U.S., improving cardiovascular care options.

• The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions. • Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment. • The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.

As outbreak in Kent claims the lives of two young people, experts advise against rushing to get a vaccinePharmacies in England are reporting a surge in demand for meningitis vaccines after an outbreak in Kent claimed the lives of two young people and left others in hospital.However experts have advised against rushing to get a jab, stressing public health authorities are best placed to determine if vaccinations are required – and for whom. Continue reading...

• Telix Pharmaceuticals resubmitted its New Drug Application to the U.S. FDA on March 16, 2026, for TLX101-Px (Pixclara®), a PET imaging agent targeting gliomas in adults and pediatrics. • The agent received Orphan Drug and Fast Track designations from the FDA due to its potential to address unmet needs in post-treatment glioma management, with 18F-FET PET already in international guidelines but no U.S.-approved equivalent. • Glioblastoma multiforme (GBM), the most common aggressive primary brain cancer, affects about 22,000 new U.S. cases yearly, with recurrence nearly universal and median survival of 12-15 months post-diagnosis.